Sort
23,748 grants matching “melanoma”
Developmental Funds
$433,659Steven E Artandi · Stanford University · P30 · FY2022 · CA
Type I Interferon Responses in the Pathobiology of Anthracycline-induced Cardiotoxicity
$433,650Andrew Phillip West · Jackson Laboratory · R01 · FY2024 · HL
Histone Arginine Demethylation through Cleavage
$433,608Gongyi Zhang · National Jewish Health · R01 · FY2021 · GM
EASTERN COOPERATIVE ONCOLOGY GROUP
$433,599Fox Chase Cancer Center · U10 · FY2001 · CA
COMPUTATIONAL TOOLS FOR CANCER PROTEOMICS
$433,509William Marland Old · University Of Colorado · R01 · FY2009 · CA
Probing cellular, molecular and biomechanical barriers to immunotherapy in the tumor microenvironment with organotypic in vitro models of the tumor-lympho-immune interface
$433,439Melody A Swartz · University Of Chicago · R01 · FY2021 · CA
The population genomics of hybridization: from genetic incompatibilities to genome evolution
$433,379Molly Schumer · Stanford University · R35 · FY2024 · GM
Project 3: Identifying Targetable Epigenetic and Immuno-Oncologic Vulnerabilities in Synovial Sarcoma
$433,378Marc Ladanyi · Sloan-Kettering Inst Can Research · P50 · FY2025 · CA
Project 3: Chemokine modulation in TME for enhanced TLS formation and cross-priming/ recruitment of therapeutic CD8+ TILs
$433,366Walter J Storkus · Roswell Park Cancer Institute Corp · P01 · FY2023 · CA
The Structure and Function of S100 Proteins
$433,361David Joseph Weber · University Of Maryland Baltimore · R01 · FY2010 · GM
Sun Safety Ink! A Sun Safety Program for the Tattoo Community
$433,324Barbara Walkosz · Klein Buendel, Inc. · R01 · FY2020 · CA
Mcl-1/Bfl-1 in apoptosis and signal transduction: a structure/function approach
$433,304Maurizio Pellecchia · University Of California Riverside · R01 · FY2020 · CA
Mcl-1/Bfl-1 in apoptosis and signal transduction: a structure/function approach
$433,304Maurizio Pellecchia · University Of California Riverside · R01 · FY2021 · CA
Targeting a PHGDH metabolic vulnerability in melanoma
$433,256Florian Karreth · H. Lee Moffitt Cancer Ctr & Res Inst · R21 · FY2024 · CA
Exploring anti-sense RNAs in melanocyte transformation and melanoma formation
$433,256Florian Karreth · H. Lee Moffitt Cancer Ctr & Res Inst · R21 · FY2025 · CA
Role of histotripsy synergized CD40 signaling in the re-engineering of cold tumors
$433,173Ashish Ranjan · Oklahoma State University Stillwater · R01 · FY2022 · CA
Liquid biopsy-based toolkits for neoantigen and cognate TCR discovery for cancer immunotherapy
$433,138Wei Wei · Institute For Systems Biology · R33 · FY2022 · CA
Inhibiting Corneal Neovascularization by Targeting Tissue Factor
$433,125Hua Zhu · Ohio State University · R21 · FY2025 · EY
Shared Resource: Therapeutic Manufacturing
$433,092Ronald Manger · Fred Hutchinson Cancer Research Center · P30 · FY2015 · CA
The Genetics of Susceptibility to Mouse Plasma Cell Tumors
$433,016Beverly Mock · Division Of Basic Sciences - Nci · ZIA · FY2010 · CA
Image guided immunotherapy and targeted radionuclide therapy of metastatic melanoma
$432,877Carolyn J Anderson · University Of Missouri-Columbia · R01 · FY2021 · CA
Germline and somatic variants associated with melanoma immunophenotype
$432,530Thomas F Gajewski · University Of Chicago · R01 · FY2016 · CA
Personal tumor neoantigens for immunity against chronic lymphocytic leukemia
$432,500Catherine Ju-Ying Wu · Dana-Farber Cancer Inst · R01 · FY2015 · CA
The Function of CDK5 in Metastasis
$432,500Piotr Sicinski · Dana-Farber Cancer Inst · R01 · FY2022 · CA
The Function of CDK5 in Metastasis
$432,500Piotr Sicinski · Dana-Farber Cancer Inst · R01 · FY2023 · CA